Heron Therapeutics v. Mylan: Cinvanti® Patent Dispute Dismissed Without Prejudice
Heron Therapeutics sued Mylan over 10 patents protecting Cinvanti® injectable emulsion (130 mg/18 mL), an IV aprepitant formulation for chemotherapy-induced nausea. After 599 days of litigation in the Delaware District Court, the parties resolved the dispute by stipulated dismissal without prejudice — preserving both sides’ ability to re-engage.
Ten-Patent ANDA Battle Over IV Aprepitant Ends in Structured Settlement
On September 15, 2023, Heron Therapeutics, Inc. filed suit against Mylan, NV in the U.S. District Court for the District of Delaware, asserting infringement of ten U.S. patents covering Cinvanti® — its proprietary injectable emulsion formulation of aprepitant (130 mg/18 mL) indicated for prevention of chemotherapy-induced nausea and vomiting. The patents span formulation chemistry, dosing methods, and emulsion stabilisation technology across a portfolio built from application filings dating back to the mid-2010s.
The case was resolved on May 6, 2025, when the parties filed a stipulated order of dismissal without prejudice before Judge William C. Bryson. The dismissal was entered on the basis of a settlement described as supported by ‘good cause and valuable consideration,’ with all claims, counterclaims, and affirmative defenses dismissed and each party bearing its own costs. Critically, the court retained jurisdiction to adjudicate any disputes arising from the settlement agreement itself.
At 599 days, the timeline is broadly consistent with ANDA litigation settlements that resolve before trial but after substantive pre-trial activity. The financial terms and any licensing arrangements remain confidential — typical for pharmaceutical ANDA settlements. The dismissal without prejudice, rather than with prejudice, is notable: it suggests the parties may have structured a consent judgment or licensing agreement that conditions future re-filing rights, though the public record does not confirm this.
Filing to Dismissed without Prejudice in 599 days
599 days — roughly 20 months from filing to stipulated dismissal, consistent with pre-trial ANDA settlements
Dismissed without prejudice: what the stipulated order means for both parties
Dismissal without prejudice preserves future claims
A dismissal without prejudice means neither Heron nor Mylan is barred from re-litigating the same patents and ANDA in the future. Unlike a with-prejudice dismissal — which extinguishes claims permanently — this order leaves the litigation door open. In ANDA contexts, such dismissals frequently accompany a licensing or consent judgment agreement that governs when and how a generic may enter the market, making the confidential settlement terms the operative commercial instrument.
Claims remain re-fileableHeron’s ten-patent portfolio survives without adverse merits ruling
Because the case was dismissed without a court ruling on validity or infringement, Heron’s ten Cinvanti® patents emerge from this litigation without any judicial finding against them. The patents retain full presumption of validity under 35 U.S.C. § 282. The settlement — described as providing ‘valuable consideration’ to Heron — suggests the company secured commercial terms, potentially including a market-entry date for Mylan’s generic, without the risk of an adverse validity finding at trial.
Portfolio validity intactMylan avoids validity trial but ANDA entry date likely negotiated
Mylan avoids the risk of an injunction or enhanced damages finding, and — crucially — avoids a court ruling that could have invalidated or limited Heron’s patents in ways beneficial to other ANDA filers. The ‘valuable consideration’ language indicates Mylan likely received a defined market-entry date or licensing rights. However, the dismissal without prejudice means Mylan cannot use this resolution to assert res judicata against Heron’s patents in any subsequent dispute.
Entry terms remain confidentialTen-patent ANDA settlements signal strong branded formulation strategies
Heron’s decision to assert ten patents in a single ANDA action is consistent with a layered formulation-patent strategy designed to extend exclusivity on injectable emulsion technology. For other specialty pharma companies, this case reinforces that building a dense patent thicket around complex injectable formulations can deter generic entry or drive favorable settlement terms. Competing ANDA filers for IV aprepitant should monitor any future consent judgment filing, which may contain market-entry dates binding on Mylan.
Formulation thicket strategy validatedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Heron Therapeutics, Inc. | Company | Specialty biopharmaceutical company — holder of US10624850B2 and 9 related Cinvanti® patentsSearch in Eureka ↗ |
| Defendant | Mylan, NV | Company | Global generics manufacturer Mylan, NV — ANDA filer seeking to market generic IV aprepitant emulsionSearch in Eureka ↗ |
| Plaintiff counsel | Anthony David Raucci | Attorney | Counsel for Heron Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Bruce M. Wexler | Attorney | Counsel for Heron Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christopher P. Hill | Attorney | Counsel for Heron Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Isaac S. Ashkenazi | Attorney | Counsel for Heron Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Heron Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for Heron Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Mark Russell Sperling | Attorney | Counsel for Heron Therapeutics, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Heron Therapeutics, Inc.Search in Eureka ↗ |
| Defendant counsel | Andrew Mark Moshos | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Bindu Ann George Palapura | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | David Ellis Moore | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Elham F. Steiner | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Jody Karol | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Kristina M. Hanson | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Mark A. Hayden | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Sean M. Anderson | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Shannon P. Gillespie McComb | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Tung-On Kong | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Wendy L. Devine | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant law firm | Potter, Anderson & Corroon LLP | Law Firm | Representing Mylan, NVSearch in Eureka ↗ |
| Defendant law firm | Wilson Sonsini Goodrich & Rosati, LLP | Law Firm | Representing Mylan, NVSearch in Eureka ↗ |
| Presiding judge | Judge William C. Bryson | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation’s language — ‘good cause and valuable consideration recognized by Heron and Mylan’ — is standard boilerplate for ANDA settlements but deliberately signals a bilateral exchange of value rather than a unilateral concession. The court’s retention of jurisdiction is legally significant: it converts the settlement agreement into an instrument enforceable by court order, not merely as a contract. The absence of any merit-based finding means neither party’s litigation position was formally adjudicated, leaving the ten Cinvanti® patents unchallenged on the public record.
US10624850B2 — Injectable aprepitant emulsion formulations (Cinvanti®)
The ten asserted patents collectively protect Cinvanti® — an injectable lipid emulsion formulation of aprepitant, an NK1 receptor antagonist approved for prevention of chemotherapy-induced nausea and vomiting (CINV). The portfolio spans formulation composition patents (emulsion chemistry, excipient ratios, particle size parameters), method-of-use patents (dosing regimens, IV administration protocols), and manufacturing process claims. Application filings range from the mid-2010s through the early 2020s, reflecting a deliberate lifecycle extension strategy built around the core aprepitant molecule.
For the CINV market, Cinvanti®’s IV formulation offers a clinical differentiation from oral aprepitant (Emend®) — particularly valuable in patients unable to take oral medications. Heron’s decision to build a ten-patent portfolio around this single product reflects the commercial importance of injectable emulsion exclusivity in oncology supportive care. Generic entrants must design around or successfully challenge all ten patent families to achieve unencumbered market entry — a bar that appears to have driven Mylan toward settlement rather than a costly multi-patent trial.
Should you run an FTO against Heron’s Cinvanti® patent portfolio?
Any company developing an IV aprepitant emulsion product — whether as an ANDA filer, a 505(b)(2) applicant, or a biosimilar-adjacent injectable formulation developer — faces direct exposure to Heron’s ten-patent portfolio. The portfolio’s breadth across formulation, method-of-use, and manufacturing claims means a clearance opinion must evaluate each family independently. The Mylan settlement confirms these patents are actively enforced and that Heron is prepared to litigate through nearly two years of district court proceedings to protect them.
PatSnap Eureka’s FTO Search Agent enables systematic claim-by-claim mapping of all ten Cinvanti® patent families against proposed product specifications — identifying which claims present the highest infringement risk and surfacing prior art for invalidity analysis. Eureka’s portfolio visualisation tools also allow R&D teams to identify design-around opportunities across emulsion excipient selection, particle size parameters, and dosing regimen claims before committing to an ANDA filing strategy.
Run a freedom-to-operate analysis on US10624850B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases involving injectable pharmaceutical formulations
Explore comparable ANDA infringement actions in Delaware District Court involving multi-patent assertions over injectable emulsion and specialty pharmaceutical formulations.
What this case signals for injectable pharmaceutical IP strategy
Heron’s ten-patent ANDA action against Mylan reveals how specialty pharma companies use dense formulation portfolios to control generic market entry.
Multi-patent ANDA filings shift settlement leverage to brand holders
Asserting ten patents in a single ANDA case dramatically raises the cost and complexity of generic challengers’ invalidity analysis. Even where individual patents may be vulnerable, the aggregate litigation burden often drives settlement on terms favorable to the brand — as appears to have occurred here with ‘valuable consideration’ flowing to Heron.
Court-retained jurisdiction is a key post-settlement enforcement tool
The Delaware District Court’s explicit retention of jurisdiction over settlement disputes gives Heron a streamlined enforcement mechanism if Mylan breaches any agreed market-entry date or licensing term. IP teams monitoring similar ANDA settlements should note this provision as a signal that the underlying agreement contains binding commercial obligations.
Heron v Mylan — key questions answered
Heron asserted ten U.S. patents in this action: US10624850B2, US10953018B2, US11744800B2, US9974793B2, US9974794B2, US11173118B2, US10500208B2, US9808465B2, US9561229B2, and US9974742B2. All relate to Cinvanti® (aprepitant injectable emulsion 130 mg/18 mL), covering formulation chemistry, dosing methods, and emulsion manufacturing processes.
The parties stipulated to dismissal without prejudice, meaning neither is barred from future litigation on the same patents. In ANDA contexts, this structure typically accompanies a confidential settlement containing a defined market-entry date or licensing terms. Dismissal without prejudice preserves Heron’s ability to re-file if Mylan breaches the settlement, while the court’s retained jurisdiction provides a streamlined enforcement mechanism.
Cinvanti® (aprepitant injectable emulsion, 130 mg/18 mL) is an IV NK1 receptor antagonist manufactured by Heron Therapeutics for prevention of chemotherapy-induced nausea and vomiting. As an intravenous formulation, it offers clinical advantages over oral aprepitant in certain patient populations. Its commercial value makes it a target for ANDA challenges from generic manufacturers seeking to enter the market before Heron’s patent exclusivity expires.
The court’s explicit retention of jurisdiction over settlement-related disputes means any future breach claim — such as Mylan launching its generic product before an agreed date — can be brought directly before Judge Bryson without filing a new lawsuit. This is a significant enforcement tool for Heron and is a standard feature of complex ANDA settlements where ongoing compliance with market-entry conditions must be monitored.
The case ran for 599 days (approximately 20 months) from filing on September 15, 2023 to dismissal on May 6, 2025. This duration is broadly consistent with ANDA cases that settle after substantive pre-trial activity — including claim construction briefing and potentially expert discovery — but before a scheduled trial date. Many ANDA cases in Delaware resolve in the 18–30 month window as parties assess litigation risk ahead of trial.
PatSnap Eureka searches patents and litigation data to answer instantly.